Giuseppe Boriani1, Cecile Laroche2, Igor Diemberger3, Elisa Fantecchi4, Mircea Ioachim Popescu5, Lars Hvilsted Rasmussen6, Gheorghe-Andrei Dan7, Zbigniew Kalarus8, Luigi Tavazzi9, Aldo P Maggioni10, Gregory Y H Lip11. 1. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, S. Orsola-Malpighi University Hospital, Via Massarenti 9, Bologna 40138, Italy Cardiology Department, University of Modena and Reggio Emilia, Policlinico di Modena, Viale del Pozzo, 71, 41124 Modena, Italy giuseppe.boriani@unimore.it. 2. EURObservational Research Programme Department, European Society of Cardiology, Sophia Antipolis, France. 3. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, S. Orsola-Malpighi University Hospital, Via Massarenti 9, Bologna 40138, Italy. 4. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, S. Orsola-Malpighi University Hospital, Via Massarenti 9, Bologna 40138, Italy Cardiology Department, University of Modena and Reggio Emilia, Policlinico di Modena, Viale del Pozzo, 71, 41124 Modena, Italy. 5. Department of Cardiology, Faculty of Medicine, Oradea, Romania. 6. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark. 7. Department of Cardiology, Colentina University Hospital, Stefan cel Mare 19-21, Sector 2, Bucharest, Romania. 8. Department of Cardiology, Silesian Center for Heart Disease, ul. M Curie-Sklodowskiej 9, Zabrze 41-800, Poland. 9. Maria Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, Cotignola, Italy. 10. EURObservational Research Programme Department, European Society of Cardiology, Sophia Antipolis, France ANMCO Research Center, Firenze, Italy. 11. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK.
Abstract
AIMS: Atrial fibrillation (AF) has different presentations (first detected, paroxysmal, persistent, permanent), with uncertain impact on outcome. The aim of this study was to investigate clinical presentation, management, and outcome of paroxysmal and non-paroxysmal AFs within the EURObservational Research Programme-Atrial Fibrillation General Pilot Registry. METHODS AND RESULTS: Overall 2589 patients with available 1-year follow-up data were evaluated according to AF type. Patients with paroxysmal AF (26.8%) were younger, had lower prevalence of heart disease (particularly valvular), and major co-morbidities, as well as lower CHADS2, CHA2DS2-VASc, and HAS-BLED scores. Patients with first-detected AF (29.9%) had characteristics similar to persistent AF patients (25.9%), but lower use of oral anticoagulants. Patients with permanent AF represented 17.4% of the cohort. At 1 year, the rate of stroke/transient ischaemic attack and thromboembolism was low (0.6-1.0%) and did not differ between paroxysmal and non-paroxysmal AFs. All-cause mortality was higher in non-paroxysmal vs. paroxysmal AF (log rank test, P = 0.0018). Using a multivariable Cox model, non-paroxysmal AF was not an independent predictor of death during follow-up. Independent predictors of death were age, chronic heart failure, chronic kidney disease, diabetes, restrictive cardiomyopathy, and physical activity. CONCLUSION: In this 'real-world' contemporary observational registry, patients with non-paroxysmal AF had a worse outcome, in terms of all-cause mortality, which was related to a more severe clinical profile. The risk of stroke at 1 year was relatively low, perhaps reflecting the high rates of anticoagulation use in this cohort. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Atrial fibrillation (AF) has different presentations (first detected, paroxysmal, persistent, permanent), with uncertain impact on outcome. The aim of this study was to investigate clinical presentation, management, and outcome of paroxysmal and non-paroxysmal AFs within the EURObservational Research Programme-Atrial Fibrillation General Pilot Registry. METHODS AND RESULTS: Overall 2589 patients with available 1-year follow-up data were evaluated according to AF type. Patients with paroxysmal AF (26.8%) were younger, had lower prevalence of heart disease (particularly valvular), and major co-morbidities, as well as lower CHADS2, CHA2DS2-VASc, and HAS-BLED scores. Patients with first-detected AF (29.9%) had characteristics similar to persistent AFpatients (25.9%), but lower use of oral anticoagulants. Patients with permanent AF represented 17.4% of the cohort. At 1 year, the rate of stroke/transient ischaemic attack and thromboembolism was low (0.6-1.0%) and did not differ between paroxysmal and non-paroxysmal AFs. All-cause mortality was higher in non-paroxysmal vs. paroxysmal AF (log rank test, P = 0.0018). Using a multivariable Cox model, non-paroxysmal AF was not an independent predictor of death during follow-up. Independent predictors of death were age, chronic heart failure, chronic kidney disease, diabetes, restrictive cardiomyopathy, and physical activity. CONCLUSION: In this 'real-world' contemporary observational registry, patients with non-paroxysmal AF had a worse outcome, in terms of all-cause mortality, which was related to a more severe clinical profile. The risk of stroke at 1 year was relatively low, perhaps reflecting the high rates of anticoagulation use in this cohort. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Vincenzo Livio Malavasi; Elisa Fantecchi; Virginia Tordoni; Laura Melara; Andrea Barbieri; Marco Vitolo; Gregory Y H Lip; Giuseppe Boriani Journal: Intern Emerg Med Date: 2020-11-07 Impact factor: 3.397
Authors: Jeanne E Poole; Tristram D Bahnson; Kristi H Monahan; George Johnson; Hoss Rostami; Adam P Silverstein; Hussein R Al-Khalidi; Yves Rosenberg; Daniel B Mark; Kerry L Lee; Douglas L Packer Journal: J Am Coll Cardiol Date: 2020-06-30 Impact factor: 24.094
Authors: Martijn J Tilly; Zuolin Lu; Sven Geurts; M Arfan Ikram; Bruno H Stricker; Jan A Kors; Moniek P M de Maat; Natasja M S de Groot; Maryam Kavousi Journal: Clin Res Cardiol Date: 2022-08-10 Impact factor: 6.138
Authors: Franco Giulianini; Bastiaan Geelhoed; Kathryn L Lunetta; Jeffrey R Misialek; Maartje N Niemeijer; Michiel Rienstra; Lynda M Rose; Albert V Smith; Neal A Chatterjee; Dan E Arking; Patrick T Ellinor; Jan Heeringa; Honghuang Lin; Steven A Lubitz; Elsayed Z Soliman; Niek Verweij; Alvaro Alonso; Emelia J Benjamin; Vilmundur Gudnason; Bruno H C Stricker; Pim Van Der Harst; Daniel I Chasman; Christine M Albert Journal: Circulation Date: 2016-12-14 Impact factor: 29.690
Authors: Wern Yew Ding; José Miguel Rivera-Caravaca; Francisco Marin; Vanessa Roldán; Gregory Y H Lip Journal: J Thromb Thrombolysis Date: 2022-04-15 Impact factor: 5.221
Authors: Jean-Pierre Bassand; Gabriele Accetta; Wael Al Mahmeed; Ramon Corbalan; John Eikelboom; David A Fitzmaurice; Keith A A Fox; Haiyan Gao; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Gloria Kayani; Karen Pieper; Alexander G G Turpie; Martin van Eickels; Freek W A Verheugt; Ajay K Kakkar Journal: PLoS One Date: 2018-01-25 Impact factor: 3.240
Authors: Renate B Schnabel; Ladislav Pecen; Nargiz Rzayeva; Markus Lucerna; Yanish Purmah; Francisco M Ojeda; Raffaele De Caterina; Paulus Kirchhof Journal: J Am Heart Assoc Date: 2018-05-18 Impact factor: 5.501